ArticleAdvanced healthcare materials2026
Water-Activated Phospholipid Phase-Separation Gel as an Immunomodulatory Anti-Adhesion Barrier for Postoperative Adhesion Prevention.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Postoperative adhesions remain a major complication after abdominal surgery, and current polymeric barriers often show limited tissue retention and biocompatibility. Here, we establish a water-activated phospholipid barrier strategy for postoperative adhesion prevention by converting a depot-forming phospholipid phase-separation gel (PPSG) into a gram-scale surgical barrier. In this study, solvent identity acts as a functional design determinant rather than a passive solubilizer, governing hydration-triggered gel reinforcement, intraperitoneal residence, and tolerability. Replacing ethanol with propylene glycol strengthened the gel matrix, improved barrier activation, and enabled gram-scale administration without hepatic toxicity associated with ethanol-based PPSG. Mechanistically, the structured phospholipid barrier retained gel-state immunomodulatory activity, attenuating macrophage-driven inflammatory responses and suppressing NF-κB-associated signaling. In a rat peritoneal-cecum abrasion model, propylene glycol-based PPSG completely prevented macroscopic adhesions. Together, these findings establish a water-activated phospholipid barrier platform for converting depot-forming phospholipid systems into active surgical barriers that combine durable physical separation with local immunomodulation.
Indexed as
Identifiers
42717399What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.